JP7581055B2 - 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法 - Google Patents

新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法 Download PDF

Info

Publication number
JP7581055B2
JP7581055B2 JP2020573107A JP2020573107A JP7581055B2 JP 7581055 B2 JP7581055 B2 JP 7581055B2 JP 2020573107 A JP2020573107 A JP 2020573107A JP 2020573107 A JP2020573107 A JP 2020573107A JP 7581055 B2 JP7581055 B2 JP 7581055B2
Authority
JP
Japan
Prior art keywords
hpβcd
less
ppm
equal
preferably less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529243A (ja
JPWO2020002851A5 (https=
JP2021529243A5 (https=
Inventor
ビュフ クロティルド
デラートレ ジョエル
ヴィアッツ ヴァンサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roquette Freres SA
Original Assignee
Roquette Freres SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1855952A external-priority patent/FR3083234B1/fr
Application filed by Roquette Freres SA filed Critical Roquette Freres SA
Publication of JP2021529243A publication Critical patent/JP2021529243A/ja
Publication of JPWO2020002851A5 publication Critical patent/JPWO2020002851A5/ja
Publication of JP2021529243A5 publication Critical patent/JP2021529243A5/ja
Priority to JP2024130931A priority Critical patent/JP2024150779A/ja
Application granted granted Critical
Publication of JP7581055B2 publication Critical patent/JP7581055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2020573107A 2018-06-29 2019-06-28 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法 Active JP7581055B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024130931A JP2024150779A (ja) 2018-06-29 2024-08-07 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1855952A FR3083234B1 (fr) 2018-06-29 2018-06-29 Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
FR1855952 2018-06-29
FR1902375 2019-03-08
FR1902375 2019-03-08
PCT/FR2019/051602 WO2020002851A1 (fr) 2018-06-29 2019-06-28 NOUVELLE HYDROXYPROPYL-β-CYCLODEXTRINE ET SON PROCÉDÉ DE PRÉPARATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024130931A Division JP2024150779A (ja) 2018-06-29 2024-08-07 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法

Publications (4)

Publication Number Publication Date
JP2021529243A JP2021529243A (ja) 2021-10-28
JPWO2020002851A5 JPWO2020002851A5 (https=) 2023-08-10
JP2021529243A5 JP2021529243A5 (https=) 2023-08-10
JP7581055B2 true JP7581055B2 (ja) 2024-11-12

Family

ID=67551566

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573107A Active JP7581055B2 (ja) 2018-06-29 2019-06-28 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法
JP2024130931A Pending JP2024150779A (ja) 2018-06-29 2024-08-07 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024130931A Pending JP2024150779A (ja) 2018-06-29 2024-08-07 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法

Country Status (10)

Country Link
US (1) US12522670B2 (https=)
EP (1) EP3814386A1 (https=)
JP (2) JP7581055B2 (https=)
KR (1) KR102912248B1 (https=)
CN (1) CN112334494A (https=)
CA (1) CA3104568A1 (https=)
IL (1) IL279845A (https=)
MX (1) MX2020013689A (https=)
SG (1) SG11202013126QA (https=)
WO (1) WO2020002851A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7607935B2 (ja) 2019-01-03 2025-01-06 サイクラリティ・セラピューティクス・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
JP2024064599A (ja) * 2022-10-28 2024-05-14 国立大学法人 熊本大学 細胞内コレステロール輸送障害に起因する疾患又は障害の治療、予防又は改善用組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102040675A (zh) 2010-12-22 2011-05-04 石药集团石家庄高科医药科技开发有限公司 一种羟丙基-β-环糊精的制备方法
CN102558394A (zh) 2010-12-07 2012-07-11 石药集团中奇制药技术（石家庄）有限公司 羟丙基-β-环糊精的制备方法
JP2016153401A (ja) 2010-09-13 2016-08-25 ベヴ−アールエックス、インク． 不快味マスキング剤を有する水性薬物送達システム
JP2017500310A (ja) 2013-12-13 2017-01-05 ロケット フレールＲｏｑｕｅｔｔｅ Ｆｒｅｒｅｓ Ｈｄｌコレステロール値を上昇させることによって疾病を治療かつ／または予防する、メチルシクロデキストリンをベースとする組成物
CN108034010A (zh) 2017-12-29 2018-05-15 山东滨州智源生物科技有限公司 一种羟丙基环糊精的绿色制备方法
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
HK1009335A1 (en) * 1989-04-03 1999-05-28 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
US5096893A (en) 1989-04-03 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Regioselective substitutions in cyclodextrins
KR920008700A (ko) * 1990-10-29 1992-05-28 이헌조 데크의 테이프 삽입유무 표시방법
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
CN1155888A (zh) * 1995-06-08 1997-07-30 火箭兄弟公司 粉状羟丙基-β-环糊精组合物和其制备方法
FR2735136B1 (fr) * 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
FR2738149B1 (fr) * 1995-09-06 1997-11-14 Chauvin Lab Sa Collyre a base d'indometacine pret a l'emploi
US5744154A (en) 1995-09-06 1998-04-28 Laboratoire Chauvin S.A. Ready-to-use indomethacin-based eye lotion
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
US8791269B2 (en) 2011-07-01 2014-07-29 Fondazione Istituto Insubrico Di Ricerca Per La Vita Complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016153401A (ja) 2010-09-13 2016-08-25 ベヴ−アールエックス、インク． 不快味マスキング剤を有する水性薬物送達システム
CN102558394A (zh) 2010-12-07 2012-07-11 石药集团中奇制药技术（石家庄）有限公司 羟丙基-β-环糊精的制备方法
CN102040675A (zh) 2010-12-22 2011-05-04 石药集团石家庄高科医药科技开发有限公司 一种羟丙基-β-环糊精的制备方法
JP2017500310A (ja) 2013-12-13 2017-01-05 ロケット フレールＲｏｑｕｅｔｔｅ Ｆｒｅｒｅｓ Ｈｄｌコレステロール値を上昇させることによって疾病を治療かつ／または予防する、メチルシクロデキストリンをベースとする組成物
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
CN108034010A (zh) 2017-12-29 2018-05-15 山东滨州智源生物科技有限公司 一种羟丙基环糊精的绿色制备方法

Also Published As

Publication number Publication date
US12522670B2 (en) 2026-01-13
EP3814386A1 (fr) 2021-05-05
JP2024150779A (ja) 2024-10-23
KR20210027279A (ko) 2021-03-10
IL279845A (en) 2021-03-01
JP2021529243A (ja) 2021-10-28
SG11202013126QA (en) 2021-02-25
KR102912248B1 (ko) 2026-01-15
US20210253746A1 (en) 2021-08-19
WO2020002851A1 (fr) 2020-01-02
MX2020013689A (es) 2021-05-12
CA3104568A1 (fr) 2020-01-02
CN112334494A (zh) 2021-02-05

Similar Documents

Publication Publication Date Title
JP2024150779A (ja) 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法
KR100349754B1 (ko) 제약조성물
US20100087392A1 (en) Complexes of ibuprofen, cyclodextrins and ternary agents and the use thereof in pharmaceutics
Khan et al. Cyclodextrin: an overview
HK1208177A1 (en) Racecadotril liquid compositions
JP3509866B2 (ja) 薬物等の疎水性化合物を溶解するために特に使用可能な新規シクロデキストリン誘導体およびその調製方法
US11098135B2 (en) Methylated cyclodextrins and methods for the production thereof
CN1879887B (zh) 基于水溶性环糊精聚合物的难溶性药物给药系统
KR20240160120A (ko) 하이드록시프로필-베타-사이클로덱스트린의 조성물 및 이의 정제 방법
Lemesle-Lamache et al. Study of β-cyclodextrin and ethylated β-cyclodextrin salbutamol complexes, in vitro evaluation of sustained-release behaviour of salbutamol
JP4124483B2 (ja) ミセル様水性組成物及び疎水性薬物の可溶化方法
EP1272531B8 (en) Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
CN101314045A (zh) 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
Arora et al. Physicochemical characterization and evaluation of telmisartan: hydroxypropyl-βcyclodextrin: Tween 80 inclusion complex
HRP980155A2 (en) Pharmaceutical compositions containing propanamine derivatives and cyclodextrin
AU2021398541A1 (en) Pharmaceutical composition containing propofol, a cyclodextrin or a cyclodextrin derivative and a pharmaceutically acceptable salt
VARGANICI et al. β-Cyclodextrin as carrier for different guest molecules in bioapplications–a minireview on the thermal complexation studies by differential scanning calorimetry
JP5157447B2 (ja) メキタジンとシクロデキストリンと相互作用剤を含む複合体
US20040242538A1 (en) Method to improve complexation efficacy and produce high-energy cylodextrincomplexes
JPH01131202A (ja) 新規な腸溶性分子カプセル
KR920008700B1 (ko) 수-난용성 또는 수-불안정성 약제와 β-사이클로덱스트린 에테르의 수용성 복합체의 제조방법
Loftsson et al. Enhanced complexation efficacy of cyclodextrins
FR3083234A1 (fr) Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
ORMANCE M. Ghorabº, AH Nadaº, MM Ghorab º „and. M. Hammady
JPWO2001041757A1 (ja) シクロデキストリン含有医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240807

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241030

R150 Certificate of patent or registration of utility model

Ref document number: 7581055

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150